{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:22:15Z","timestamp":1761895335197},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":3004,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1093\/annonc\/mdr388","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T20:11:18Z","timestamp":1315599078000},"page":"vi59-vi63","source":"Crossref","is-referenced-by-count":60,"special_numbering":"S6","title":["Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"22","author":[{"given":"M.","family":"Dreyling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ghielmini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr388_bb0010","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunhisto-chemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr388_bb0015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr388_bb0020","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr388_bb0025","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr388_bb0030","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr388_bb0035","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr388_bb0040","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low grade follicular lymphoma? Results of a long term follow-up study of patients treated at Stanford University","volume":"14","author":"MacManus","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr388_bb0045","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","article-title":"Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy","volume":"22","author":"Advani","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr388_bb0050","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr388_bb0055","doi-asserted-by":"crossref","unstructured":"KM Ardeshna P Smith W Qian. An intergroup randomised trial of rituximab vs a watch & wait approach in patients with advanced stage, asymptomatic, non-bulky follicular lymphoma. ASH 2010 Congress, December 2010; abstract 6.","DOI":"10.1182\/blood.V116.21.6.6"},{"issue":"no 11","key":"10.1093\/annonc\/mdr388_bb0060","volume":"110","author":"Rummel","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr388_bb0065","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr388_bb0070","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr388_bb0075","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisolone alone in patients with previously untreated advanced follicular lymphoma","volume":"28","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr388_bb0080","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr388_bb0085","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr388_bb0090","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-Tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdr388_bb0095","first-page":"4480","volume":"28","author":"Martinelli","year":"2010","journal-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98J Clin Oncol"},{"key":"10.1093\/annonc\/mdr388_bb0100","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3324\/haematol.2009.005819","article-title":"Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance","volume":"94","author":"Ziakas","year":"2009","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdr388_bb0105","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","article-title":"Meta-analysis to evaluate the role of interferon in follicular lymphoma","volume":"23","author":"Rohatiner","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr388_bb0110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr388_bb0115","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr388_bb0120","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma\u2014results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr388_bb0125","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr388_bb0130","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr388_bb0135","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS. Final results with a median follow-up of nine years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr388_bb0140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-006-0207-0","article-title":"Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma\u2014role of radioimmunotherapy","volume":"86","author":"Dreyling","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdr388_bb0145","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr388_bb0150","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr388_bb0155","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr388_bb0160","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"Van Besnien","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr388_bb0165","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr388_bb0170","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V116.21.855.855","article-title":"Result of FDG PET-CT imaging after immunochemotherapy induction is a powerful and independent progsnotic indicator of outcome for patients with follicular lymphoma","volume":"116","author":"Trotman","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdr388_bb0175","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2004-06-2490","article-title":"Quantitative PCR of bone marrow BCL2\/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma","volume":"105","author":"Rambaldi","year":"2005","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419388027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419388027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/suppl_6\/vi59\/758769\/mdr388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T19:10:57Z","timestamp":1590693057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419388027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":34,"alternative-id":["S0923753419388027"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr388","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}